Patent application number | Description | Published |
20090215776 | Organic compounds - Compounds of formula I | 08-27-2009 |
20100029670 | ORGANIC COMPOUNDS - The present invention relates to compounds of formula (I) | 02-04-2010 |
20100041887 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS - Compounds of formula I | 02-18-2010 |
20100168132 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS - Compounds of Formula (I) ; in salt or zwitterionic form wherein R | 07-01-2010 |
20110230483 | Pyridine and Pyrazine derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 09-22-2011 |
20110251205 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST - The present invention relates to compounds of formula (I) | 10-13-2011 |
20110251206 | Squaramide derivatives as CXCR2 antagonist - The present invention relates to compounds of formula (I) | 10-13-2011 |
20120277232 | Pyridine and Pyrazine Derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 11-01-2012 |
20130005735 | ORGANIC COMPOUNDS - The present invention relates to compounds of formula (I) | 01-03-2013 |
20140135329 | Pyridine and Pyrazine derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 05-15-2014 |
20140206768 | CHOLINE SALT OF AN ANTI-INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUND - 6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide choline, solid pharmaceutical compositions and oral dosage forms that contain said compound, and a method of using such compositions and oral dosage forms to treat people who have inflammatory, obstructive or allergic conditions and diseases are disclosed. | 07-24-2014 |
20140213594 | ORGANIC COMPOUNDS - The present invention relates to compounds of formula (I) | 07-31-2014 |
20150045364 | Pyridine and Pyrazine derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 02-12-2015 |